{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:03:32Z","timestamp":1760889812290},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11864-019-0629-2","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T12:05:20Z","timestamp":1552565120000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"20","author":[{"given":"Dai","family":"Ogata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"629_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1524-4725.2009.01095.x","volume":"35","author":"A Jambusaria-Pahlajani","year":"2009","unstructured":"Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35:574\u201385.","journal-title":"Dermatol Surg"},{"key":"629_CR2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","volume":"51","author":"A Stratigos","year":"2015","unstructured":"Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:1989\u20132007.","journal-title":"Eur J Cancer"},{"issue":"4","key":"629_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hed.24683","volume":"39","author":"N Hirshoren","year":"2017","unstructured":"Hirshoren N, Danne J, Dixon BJ, Magarey M, Kleid S, Webb A, et al. Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2017;39(4):772\u20138.","journal-title":"Head Neck"},{"issue":"Suppl 1","key":"629_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1017\/S0022215112002101","volume":"127","author":"JT Wang","year":"2013","unstructured":"Wang JT, Palme CE, Wang AY, Morgan GJ, Gebski V, Veness MJ. In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome. J Laryngol Otol. 2013;127(Suppl 1):S2\u20137.","journal-title":"J Laryngol Otol"},{"issue":"5","key":"629_CR5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/cncr.24855","volume":"116","author":"VI Forest","year":"2010","unstructured":"Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer. 2010;116(5):1298\u2013304.","journal-title":"Cancer"},{"issue":"12","key":"629_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/hed.23843","volume":"37","author":"C Schmidt","year":"2015","unstructured":"Schmidt C, Martin JM, Khoo E, Plank A, Grigg R. Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head Neck. 2015;37(12):1808\u201315.","journal-title":"Head Neck"},{"issue":"2","key":"629_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11864-014-0280-x","volume":"15","author":"C Bejar","year":"2014","unstructured":"Bejar C, Maubec E. Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options in Oncol. 2014;15(2):302\u201320.","journal-title":"Curr Treat Options in Oncol"},{"issue":"25","key":"629_CR8","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","volume":"29","author":"E Maubec","year":"2011","unstructured":"Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419\u201326.","journal-title":"J Clin Oncol"},{"issue":"5","key":"629_CR9","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","volume":"18","author":"CM Lewis","year":"2012","unstructured":"Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435\u201346.","journal-title":"Clin Cancer Res"},{"key":"629_CR10","first-page":"885","volume":"33","author":"AS Weinberg","year":"2007","unstructured":"Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33:885\u201399.","journal-title":"Dermatol Surg"},{"issue":"4","key":"629_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"\u2022\u2022 Migden MR, Rischin D, Schmults CD, Hauschild A, Lewis KD, Chung CH, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351 This article is the first cemiplimab, an anti-PD-L1 antibody, prospective trial in patients with advanced cSCC for evaluating efficacy and safety. It indicates anti-PD-L1 antibody therapy significantly improves the prognosis of advanced cSCC patients.","journal-title":"N Engl J Med"},{"issue":"2","key":"629_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CCO.0000000000000359","volume":"29","author":"S Ribero","year":"2017","unstructured":"Ribero S, Stucci LS, Daniels GA, Borradori L. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017;29(2):129\u201335.","journal-title":"Curr Opin Oncol"},{"key":"629_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/carcin\/bgi123","volume":"26","author":"P Boukamp","year":"2005","unstructured":"Boukamp P. Nonmelanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005;26:1657\u201367.","journal-title":"Carcinogenesis"},{"key":"629_CR14","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/1097-0142(19931001)72:7<2186::AID-CNCR2820720720>3.0.CO;2-2","volume":"72","author":"WL Barrett","year":"1993","unstructured":"Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer. 1993;72:2186\u20139.","journal-title":"Cancer"},{"key":"629_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.gendis.2014.08.005","volume":"1","author":"Y Kim","year":"2014","unstructured":"Kim Y, He YY. Ultraviolet radiation-induced nonmelanoma skin cancer: regulation of DNA damage repair and inflammation. Genes Dis. 2014;1:188\u201398.","journal-title":"Genes Dis"},{"issue":"4","key":"629_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1751-1097.1996.tb03040.x","volume":"63","author":"H Mukhtar","year":"1996","unstructured":"Mukhtar H, Elmets CA. Photocarcinogenesis: mechanisms, models and human health implications. Photochem Photobiol. 1996;63(4):356\u20137.","journal-title":"Photochem Photobiol"},{"key":"629_CR17","doi-asserted-by":"publisher","first-page":"e110928","DOI":"10.1371\/journal.pone.0110928","volume":"9","author":"A Freeman","year":"2014","unstructured":"Freeman A, Bridge JA, Maruthayanar P, Overgaard NH, Jung JW, Simpson F, et al. Comparative immune phenotypic analysis of cutaneous squamous cell carcinoma and intraepidermal carcinoma in immune-competent individuals: proportional representation of CD8\u00fe T-cells but not FoxP3\u00fe regulatory T-cells is associated with disease stage. PLoS One. 2014;9:e110928.","journal-title":"PLoS One"},{"issue":"5","key":"629_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.pathol.2017.04.004","volume":"49","author":"E Roper","year":"2017","unstructured":"Roper E, Lum T, Palme CE, Ashford B, Ch\u2019ng S, Ranson M, et al. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology. 2017;49(5):499\u2013505.","journal-title":"Pathology"},{"key":"629_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"629_CR20","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","volume":"78","author":"A Markham","year":"2018","unstructured":"\u2022 Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841\u20136 This article summarizes the milestones in the development of cemiplimab and ongoing clinical trials.","journal-title":"Drugs"},{"key":"629_CR21","unstructured":"FDA. FDA approves first treatment for advanced form of the second most common skin cancer. 2018. \n                      https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm622044.htm\n                      \n                    . Accessed 2 Jan 2019."},{"key":"629_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamadermatol.2015.2705","volume":"152","author":"AL Chang","year":"2016","unstructured":"Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol. 2016;152:106\u20138.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"629_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"629_CR24","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/bjd.14642","volume":"175","author":"L Borradori","year":"2016","unstructured":"Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175(6):1382\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"629_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bjd.14664","volume":"176","author":"JK Winkler","year":"2017","unstructured":"Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fr\u00f6hling S, Penzel R, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017;176(2):498\u2013502.","journal-title":"Br J Dermatol"},{"key":"629_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","volume":"77","author":"A Hauschild","year":"2017","unstructured":"Hauschild A, Eichstaedt J, M\u00f6bus L, K\u00e4hler K, Weichenthal M, Schwarz T, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer. 2017;77:84\u20137.","journal-title":"Eur J Cancer"},{"key":"629_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","volume":"83","author":"T Deinlein","year":"2017","unstructured":"Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer. 2017;83:99\u2013102.","journal-title":"Eur J Cancer"},{"issue":"4","key":"629_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","volume":"153","author":"ML Stevenson","year":"2017","unstructured":"Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299\u2013303.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"629_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamadermatol.2016.3884","volume":"153","author":"DC Tran","year":"2017","unstructured":"Tran DC, Colevas AD, Chang AL. Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma. JAMA Dermatol. 2017;153(1):92\u20134.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"629_CR30","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1111\/jdv.14371","volume":"32","author":"E Degache","year":"2018","unstructured":"Degache E, Chrochet J, Simon N, Tardieu M, Trabelsi S, Moncourier M, et al. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2018;32(7):e257\u2013e258s. \n                      https:\/\/doi.org\/10.1111\/jdv.14371\n                      \n                    .","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"629_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","volume":"4","author":"GS Falchook","year":"2016","unstructured":"Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"629_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/CJI.0000000000000146","volume":"40","author":"F Day","year":"2017","unstructured":"Day F, Kumar M, Fenton L, Gedye C. Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy. J Immunother. 2017;40(1):36\u20138.","journal-title":"J Immunother"},{"key":"629_CR33","unstructured":"Merck & Co., Inc. Prescribing information: KEYTRUDA (pembrolizumab) injection, for intravenous use. 2017. \n                      https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\n                      \n                    . Accessed 2 Jan 2019."},{"key":"629_CR34","unstructured":"Bristol-Myers Squibb Company. Prescribing information: OPDIVO (nivolumab) injection, for intravenous use. 2017. \n                      https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf\n                      \n                    . Accessed 2 Jan 2019."},{"issue":"19","key":"629_CR35","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"\u2022\u2022 Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367 This article describes randomized, open-label, phase 3 trial with recurrent squamous-cell carcinoma of the head and neck and nivolumab prolonged survival, as compared with standard therapy.","journal-title":"N Engl J Med"},{"issue":"32","key":"629_CR36","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"C LQM","year":"2016","unstructured":"\u2022 LQM C, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016;34(32):3838\u201345 This article describes a phase Ib, multicenter, nonrandomized, multicohort study of pembrolizumab in patients with advanced solid tumors.","journal-title":"J Clin Oncol"},{"issue":"7","key":"629_CR37","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"\u2022 Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956\u201365 This article describes an open-label, multicenter, phase 1b trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.","journal-title":"Lancet Oncol"},{"key":"629_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2051","volume":"7","author":"I Melero","year":"2007","unstructured":"Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95\u2013106.","journal-title":"Nat Rev Cancer"},{"key":"629_CR39","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/cncr.23086","volume":"110","author":"SJ O\u2019Day","year":"2007","unstructured":"O\u2019Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614\u201327.","journal-title":"Cancer"},{"key":"629_CR40","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"L Fong","year":"2008","unstructured":"Fong L, Small EJ. Anticytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275\u201383.","journal-title":"J Clin Oncol"},{"key":"629_CR41","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","volume":"27","author":"G Manson","year":"2016","unstructured":"Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27:1199\u2013206.","journal-title":"Ann Oncol"},{"key":"629_CR42","unstructured":"Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02760498"},{"key":"629_CR43","unstructured":"Study of pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02883556"},{"issue":"19","key":"629_CR44","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"629_CR45","unstructured":"Cemiplimab in treating participants with recurrent stage III-IV hand neck squamous cell cancer before surgery. \n                      ClinicalTrials.gov\n                      \n                    . 1999. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03565783"},{"key":"629_CR46","unstructured":"Pembrolizumab in treating patients with rare tumors that cannot be removed by surgery or are metastatic. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02721732"},{"key":"629_CR47","unstructured":"T-VEC in non-melanoma skin cancer (20139157 T-VEC). \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03458117"},{"key":"629_CR48","unstructured":"Phase 1 study of CK-301 as a single agent in subjects with advanced cancers. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03212404"},{"key":"629_CR49","unstructured":"The UNSCARRed study: UNresctable Squamous Cell Carcinoma treated with Avelumab and Radical Radiotherapy (UNSCARRed). \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03737721"},{"key":"629_CR50","unstructured":"Pembrolizumab combined with cetuximab for treatment of recurrent\/metastatic head & neck squamous cell carcinoma. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03082534"},{"key":"629_CR51","unstructured":"Talimogene laherparepvec and nivolumab in treating patients with refractory lymphomas or advanced or refractory non-melanoma skin cancers. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02978625"},{"key":"629_CR52","unstructured":"A Phase 1b dose escalation\/expansion study of abexinostat in combination with pembrolizumab in patients with advanced solid tumor malignancies. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03590054"},{"key":"629_CR53","unstructured":"Trial of MG1-MAGEA3 with Ad-MAGEA3 and pembrolizumab in patients with previously treated metastatic melanoma or cutaneous squamous cell carcinoma (Pelican). \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03773744"},{"key":"629_CR54","unstructured":"Cobimetinib and atezolizumab in advanced rare tumors. \n                      ClinicalTrials.gov\n                      \n                    . 2019. Accessed 2 Jan 2019. \n                      https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03108131"},{"key":"629_CR55","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaad.2017.07.048","volume":"77","author":"WN William Jr","year":"2017","unstructured":"William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial. J Am Acad Dermatol. 2017;77:1110\u20133.","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0629-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0629-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0629-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:43:12Z","timestamp":1584060192000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0629-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0629-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"14 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dai Ogata and Tetsuya Tsuchida declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"30"}}